laurabbook@gmail.com

*November 2024* Highlights •EGFR-TKIs have improved outcomes for patients with EGFR-mutant NSCLC. •Acquired resistance occurs through complex and multifaceted mechanisms. •C797S mutation emerges in 6–12 % of patients treated with first-line osimertinib. •Fourth-generation EGFR-TKIs are active against common and resistance EGFR mutations. •Phase 1/2 clinical trials are ongoing, with promising activity…

*October 2024* Key Takeaways Osimertinib combined with savolitinib shows high response rates in EGFR-mutant, MET-overexpressed/amplified NSCLC patients post-osimertinib progression. The SAVANNAH trial confirms the safety profile of the osimertinib and savolitinib combination, with no new safety signals reported Fast track designation by the FDA underscores the potential of this combination…

*October 2024* Key Points: In EGFR-mutated non–small cell lung cancer (NSCLC), treatment with the tyrosine kinase inhibitor (TKI) osimertinib has routinely demonstrated superior survival rates; however, resistance is inevitable. MET deregulation, including the amplification of the gene (METamp), is the most common mechanism of osimertinib resistance. Dual anti-EGFR/anti-MET inhibition may be an…

*October 2024* In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together, they dive into the latest findings from ESMO 2024, focusing on key studies in lung cancer. Episode Highlights:…

*November 2024* The first patients have been dosed in 3 phase 3 trials evaluating various combinations of datapotamab deruxtecan (Dato-DXd) for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC).1 TROPION-Lung10 (NCT06357533) is investigating Dato-DXd plus rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, or rilvegostomig alone vs pembrolizumab…

*October 2024* A phase 1/2 trial (NCT06567015) evaluating STX-241 (PFL-241) for the treatment of EGFR inhibitor-resistant non–small cell lung cancer (NSCLC) has dosed its first patient.1 "We are eager to begin the clinical evaluation of PFL-241/STX-241, our mutant-selective fourth generation EGFR inhibitor, a molecule with differentiated properties that we believe…

*November 2024* In this recorded webinar, oncologist and executive medical director, Dr. Julio Hajdenberg from Black Diamond Therapeutics joined Stage IV EGFR lung cancer patients Leah Phillips and Karly Renn to explore common misconceptions about clinical trials and highlight the critical role these trials play in advancing lung cancer treatment.…

*October 2024* This is the recorded webinar discussing how immune cells can be engineered to target EGFR+ NSCLC. This webinar featured Jill Feldman and Laura Book, members of the EGFR Resisters, and Dr. Alexandre Reuben from the MD Anderson Cancer Center. Dr. Reuben is a 2023 EGFR Resisters/LUNGevity Foundation grant…

*September 2024* Durable and substantial response rates were observed when BAY 2927088 was used to treat patients with pretreated HER2-mutant non–small cell lung cancer (NSCLC), according to results from cohort D of the phase 1 SOHO-01 trial (NCT05099172) presented at the 2024 IASLC World Conference on Lung Cancer (WCLC). The objective response…